Semaglutide helps people with type 1 diabetes using automated pumps maintain stable glucose levels without increasing hypoglycemia, according to a new study published in . Led by Dr. Melissa-Rosina Pasqua at the RI-MUHC, the study highlights both the benefits and risks of off-label semaglutide use. Dr. Pasqua is also a recipient of the 91社区 Department of Medicine鈥檚 CAS pre-FRQS award, which supports early-career clinician-scientists in securing FRQS funding by providing stipend and research operating support.
鈥淲e know that off-label use of semaglutide is rising in people with type 1 diabetes, despite a lack of information to guide patients and healthcare providers on the benefits and risks associated with it,鈥� says Dr. Melissa-Rosina Pasqua, the study鈥檚 first author and Assistant Professor in the Division of Endocrinology and Metabolism at 91社区. 鈥淭his study addresses a current treatment gap and is an important stepping stone in demonstrating the benefits of this drug, as well as the ongoing need to educate patients about the risks of high ketone levels.鈥�
About the study
鈥溾�� by聽Dr. Melissa-Rosina Pasqua, Dr. Michael Tsoukas and Dr. Ahmad Haidar et al., was published in Nature Medicine.听